戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 s that combine an antiplatelet agent with an anticoagulant drug.
2 atural product that is used clinically as an anticoagulant drug.
3                   Heparin is a commonly used anticoagulant drug.
4  were interviewed for use of antiplatelet or anticoagulant drugs.
5 d in the development of new antiplatelet and anticoagulant drugs.
6 g, may occur following the administration of anticoagulant drugs.
7 f acute MI, and prior use of antiplatelet or anticoagulant drugs.
8 ng, and should facilitate development of new anticoagulant drugs.
9 287 692 patients exposed to 230 090 years of anticoagulant drugs.
10 ; P = 0.002), and the use of antiplatelet or anticoagulant drugs (33.9% of cases and 17.7% of control
11  Associations between use of antiplatelet or anticoagulant drugs and hemorrhage were evaluated among
12 etics associated with efficacy and safety of anticoagulant drugs and justify studies with larger samp
13 comparable medical resource consumption (eg, anticoagulant drugs and SFJ ligation); subsequent deep-v
14 drugs, 52% (1,647/3,194) were not prescribed anticoagulant drugs, and 25% (1,740/7,008) were not pres
15 28 had lipid-lowering drugs indicated, 3,194 anticoagulant drugs, and 7,008 antihypertensive drugs.
16  Obesity alters the pharmacokinetics of some anticoagulant drugs, and IBD patients present the added
17  from a complex precursor of the blockbuster anticoagulant drug apixaban, highlighting the utility of
18                           Several novel oral anticoagulant drugs are in development.
19                       Warfarin, an important anticoagulant drug, can exist in solution in 40 distinct
20 cade and represents an attractive target for anticoagulant drug development.
21 ated its previous report on antiplatelet and anticoagulant drugs for older patients with acute or chr
22              Seminal articles describing new anticoagulant drugs for stroke prevention in atrial fibr
23  is a good target for the development of new anticoagulant drugs for the treatment of thrombotic dise
24 g platform of selective, actively reversible anticoagulant drugs for use among patients with thrombot
25                Non-vitamin K antagonist oral anticoagulant drugs have recently expanded therapeutic o
26  contamination of the widely used lifesaving anticoagulant drug heparin in 2007 has drawn renewed att
27 es deliver an increased concentration of the anticoagulant drug hirulog to the plaque compared with u
28 itoring the blood levels of this blockbuster anticoagulant drug in specific clinical situations.
29 w provides practical guidance for the use of anticoagulant drugs in patients presenting with SVT, inc
30 ainties about risks, benefits, and dosing of anticoagulant drugs in this patient population.
31 08 participants (52.2%) used antiplatelet or anticoagulant drugs, including 514 participants (44.1%)
32               In both approaches, the use of anticoagulant drugs is recommended.
33 vailability of non-vitamin K antagonist oral anticoagulant drugs may lead to better prevention of str
34 olic stroke of undetermined source, and oral anticoagulant drugs may prove to reduce stroke risk from
35 hrombotic therapy, i.e. antiplatelet agents, anticoagulant drugs, or their combinations, require inte
36 ological prevention with low, fixed doses of anticoagulant drugs, prophylaxis remains underused in pa
37 of action, the available parenteral and oral anticoagulant drugs share the common principle of hamper
38 enefit of reversing/removing antiplatelet or anticoagulant drugs should always be weighed against the
39                   Bivalirudin is a synthetic anticoagulant drug sometimes employed as a substitute fo
40                   Heparin is a commonly used anticoagulant drug that inhibits the activities of facto
41  of aspirin and the availability of new oral anticoagulant drugs that overcome the inherent drawbacks
42                Pretreatment of mice with the anticoagulant drug warfarin to block blood factor-depend
43   VKOR is also the target of the widely used anticoagulant drug, warfarin.
44 al trials, it is likely that additional oral anticoagulant drugs will be clinically available for str
45 duronic acid being an essential component of anticoagulant drugs with diastereoselectivity superior t
46    However, the majority of patients receive anticoagulant drugs, with heterogeneous timing of initia